Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious diseases with an unmet need. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation. Eiger's lead clinical programs are focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) infection, the most serious and rapidly progressive form of viral hepatitis. Our HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger's first FDA-approved therapy is Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies - collectively known as progeria. In July 2022, the European Commission also granted Eiger marketing authorization for Zokinvy to treat progeria. For additional information about Eiger and its clinical programs, and for prescribing or safety information, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/